Sweatman Bacterial Infections of the Lungs Flashcards
what constitutes lower respiratory region
respiratory bronchioles, alveolar ducts, alveoli
symptoms of pneumonia
fever cough with our without sputum dyspnea chest pain infiltrates on radiograph (diagnostic)
unproducitve cough=
viral or mycoplasma
most important factor is successful tx. of pneumonia
early intervention (mortality decreases when you wait even 8 hours)
4 types of pneumonia
CAP
nocosomial
aspiration
immunocompromosed host
define nocosomial/hospital acquired
appears within 48 hours of arrival/admission without evidence of existing prior to arrival
most common agent 0-6 weeks for CAP
group B strep
E coli
most common agents 6 weeks-18 yrs for CAP
viruses (flu, RSV, rino, parflu, adeno)
Myco pneumonia
chlamydia pneumonia
Strep pneumonia
most common 18-40 yrs for CAP
Mycoplasma pneumonia
strep pneumonia
most common 40-65 cor CAP
Strep pneumonia H flu anaerobes (bacteroides, fusobacterium) viruses mycoplasma pneumonia
most common >65 yrs for CAP
Strep pneumonia Viruses Anaerobes H flu Gram +ve rods
most common causes of nococosmial pneumonia
S. aureus,
P aeruginosa
Most common cause of Pneumonia in Dm and Alcoholic pt.’s
Klibsielle Pneumonia
currant-jelly sputum
Pt.’s with Dm should get
annual Flu vaccine and pneumococcal pneumonia–> DM inhibits the protective proteins in airways…very susceptible to Flue and its effects….worse immune system as well
is there vaccines againts staph
no
is there vaccines against pneumococcal pneumonia
yes–> strep. pneumonia
transplant pt.’s are also susceptible to
CMV infection
gram negative aerobe that thrives in water environment
legionella pneumophilia
–> atypical causative agent for pneumonia
name the respiratory quinolones
levofloxacin
cipro
moxifloxacin
*acheive good levels in lung tissues
commonly employed for legionella
azithromycin, clarithromycin
method for tx of penumonia
catergorize based on demographics
treat with broad spectrum pending labs
(take into account individual pt., resistance, local microbe info)
Outpatient no other modifying factors
Macrolide of doxycycline
Outpaitient with COPD, no steroids of Antibiotics in 3 months
2 gen macrolide
(clarithromycin) or doxycyline
Outpaitient, COPD, steroids or antibiotics in three months
floraqunolone, or augmentin, or clarithromycin (2nd gen.) +/- cephalosporin
Nursing home
floraqunolone, or augmentin, or clarithromycin (2nd gen.) +/- cephalosporin
Hospital Ward
floraqunolone, or augmentin, or clarithromycin (2nd gen.) or azithromycin (3rd gen.) +/- cephalosporin
ICU first option
3rd gen cephalosporin+/- macrolide or piperacillin (broad)/tazobactam or floroquinilone
zosyn
piperacillin/tazobactam (beta lactamase inhibitor)
ICU with risk of P aeruginosa
antipsuedomonal florquinolone (cipro) + beta actam or
macrolide + 2 antipseudomonal agents
why adjust for recent seroid use
pt. assumed to have realignment of local flora
MOA for macrolides
50s ribo blocker–>prevent translation
MOA for tetracyclines (doxycycline)
30s ribosomal blocker–> inhibts protein synthesis
MOA for floroquinolones
DNA gyrase inhibitor–> prevents DA repication
Penicillin MOA
block cell wall cross linkage
MOA for carbapenem
blocks cell wall cross-linkage
MOA for cephalosporins
inhibit cell-call cross-linkage
3rd gen cephalosporin with anti-pseudomonal activity
cefepime
MOA for aminoglycosides (gentamicin)
30s ribosomal inhibitor
resistance mech. for macrolides
mutation of 23s rRNA, ribosomal methylation, active efflux
tetracyclines restance mech.
decreased entry/increased efflux, target insensitivity
resistance mech to floroqiunolones
mutation of DNA gyrase, active efflux